DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET

Company Participants

Rick Pauls - President, CEO & Director
Lorianne Masuoka - Chief Medical Officer
Scott Kellen - CFO & Company Secretary

Conference Call Participants

Chase Knickerbocker - Craig-Hallum
Thomas Flaten - Lake Street
François Brisebois - Oppenheimer

Operator

Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2024 Conference Call.

An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section. Before the company proceeds with its remarks, please note that the company will be making forward-looking statements on today's call.

These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results appears in the section entitled Cautionary Statement Note regarding forward-looking statements in the company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10-K and current year quarterly reports on Form 10-Q.

DiaMedica's SEC filings are available at www.sec.gov and its website. Please also note that any comments made on today's call speak only as of today, May 9, 2024, and may no longer be accurate at the time of any replay or transcript rereading.

DiaMedica disclaims any duty to update its forward-looking statements. Following the prepared remarks, we will open the phone lines for questions.

I would now like to introduce your host for today's call, Mr. Rick Pauls, DiaMedica's President and Chief Executive Officer. Mr. Pauls, you may begin.

Rick Pauls

Thank you, operator. Hello, everyone, and welcome to our first quarter conference call. I'm joined this morning by Dr. Lorianne Masuoka, our Chief Medical Officer; and Scott Kellen, our Chief Financial Officer. .

While it has been only 6 weeks since our last discussion, we have been diligently working to ramp up site activation and participant enrollment. We've also strengthened our clinical team with the addition of 3 experienced clinical operations personnel to further support the significant number of new site activations we expect over the next 6 months and the global expansion of the trial.

We are also encouraged to recently learn that the momentum of Kailikang usage in China continues to build. We now understand that upwards of 1 million patients were treated with Kailikang, the human urine-derived form of KLK1 in China in 2023.